NovaBay Pharmaceuticals, Inc. (NBY)
AMEX AMEX Primary 
NovaBay Pharmaceuticals (NBY) Upgraded to Buy: Here's Why
NovaBay Pharmaceuticals (NBY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NovaBay Pharmaceuticals, Inc. (NBY) Q2 2024 Earnings Call Transcript
NovaBay Pharmaceuticals, Inc. (NYSE:NBY ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Jody Cain - LHA, Investor Relations Justin Hall - Chief Executive Officer and General Counsel Tommy Law - Interim Chief Financial Officer Conference Call Participants Destiny Buch - Ladenburg Thalman Edward Woo - Ascendiant Capital Operator Good day, and welcome to the NovaBay Pharmaceuticals Second Quarter 2024 Financial Results Conference Call. All participants will be in listen-only mode.
Why Is NovaBay Pharmaceuticals (NBY) Stock Down 39% Today?
NovaBay Pharmaceuticals (NYSEMKT: NBY ) stock is falling hard on Thursday after the eyecare and wound care company announced results from its annual shareholder meeting. Included among the proposals in the annual shareholder meeting was a reverse stock split.
NovaBay Pharmaceuticals (NBY) Shows Fast-paced Momentum But Is Still a Bargain Stock
NovaBay Pharmaceuticals (NBY) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
